bitolterol


Also found in: Wikipedia.

bitolterol

 [bi-tol´ter-ol]
a beta-adrenergic receptor agonist used as a bronchodilator; administered by inhalation as the mesylate salt in the treatment of bronchospasm associated with asthma and the treatment and prophylaxis of bronchospasm associated with chronic obstructive airway disease, including bronchitis and pulmonary emphysema.

bitolterol

/bi·tol·ter·ol/ (bi-tol´ter-ol) a β agonist, administered by inhalation in the form of the mesylate salt as a bronchodilator.

bitolterol

[bi-tol′ter-ol]
a beta-adrenergic receptor agonist used as a bronchodilator; administered by inhalation as the mesylate salt in the treatment of bronchospasm associated with asthma and the treatment and prophylaxis of bronchospasm associated with chronic obstructive airway disease, including bronchitis and pulmonary emphysema.
References in periodicals archive ?
The more recent generation of beta-2 agonists, including albuterol, levalbuterol, bitolterol and pirbuterol, have minimum untoward cardiovascular effects, making them ideal for managing all forms of asthma.
Name of products Acidum pipemidig Atenolol Albendazol Amineptina Aciclovir Acid clavulanic Astemizole Aztreonam Bacampicillin Budesonide Bitolterol mesylate Bromcriptine masylate Bifonazol Cyclosporin Cefadroxil monohydrat Cefotaxime sodium Cyclopirox olamine Cytarabine Hcl Cetraxate Hcl Cefsulodin sodium Cefoperazone Domperidon Estazolam Fentiazac Isoconazol Ipratropium bromide Ifosfamide Ketoconazol Labetalol Hcl Minoxidil Miconazol Metroprolol tartrat Metrizamide Mianserin Hcl Midazolam malfate Metilmicin SO4 Nadolol Nicardipine Hcl Nor floxacin Oxatomide Piroxicam Praziquantel Procaterol Hcl Prazosin Hcl Sisomicin sulfat Sulprostone Tiemonium metil SO4 Tioconazole Vindesine SO4 Vecuronium bromide
2]-Agonists: Inhaled albuterol Airet(*) Proventil(*) Proventil HFA(*) Ventolin(*) Ventolin(*) Rotacaps bitolterol Tornalate(*) pirbuterol Maxair(*) terbutaline Brethaire(*) Brethine(*) (tablet only) Bricanyl(*) (tablet only) Anticholinergics: Inhaled ipratropium bromide Atrovent(*) Steroids: Tablets or liquids methylprednisolone Medrol(*) prednisone Prednisone Deltasone(*) Orasone(*) Liquid Pred(*) Prednisone Intensol(*) prednisolone Prelone(*) Pediapred(*)
It must be remembered that the later adrenergic agents (albuterol, bitolterol, pirbuterol, levalbuterol, salmeterol, formoterol, and arformoterol) are much more beta 2 specific than previous agents such as epinephrine and isoetherine.
use of the Dryhaler in combination with eight respiratory drugs -- albuterol, bitolterol, beclomethasone, budesonide, cromolyn, flunisolide, ipratropium and triamcinolone.
Dura's strategy for developing the Dryhaler drug delivery system is threefold: (1) use of the system for delivering currently available respiratory pharmaceuticals (albuterol, bitolterol, beclomethasone, ipratropium, triamcinolone, cromolyn, flunisolide and budesonide), (2) use of the system with novel respiratory drugs and (3) use of the Dryhaler for systemic pulmonary delivery of non-respiratory compounds, including peptides and proteins.
Initially, the facility will produce and analyze formulations of ipratropium, albuterol and bitolterol, with formulations of additional drugs to follow over time.
DDSI) using the Dryhaler, a proprietary dry powder inhaler drug delivery system, with formulations of three currently marketed asthma drugs -- ipratropium, bitolterol and albuterol.
Net proceeds from the Unit offering will be utilized by DDSI for development of the Dryhaler with formulations of three currently marketed drugs: ipratropium, bitolterol, and albuterol.
Dura has begun development on the formulation of four such drugs -- ipratropium, bitolterol, albuterol and beclomethasone -- for use with the Dryhaler, has had discussions with the Food and Drug Administration and is now preparing IND submissions.
We have begun development on the formulation of three currently marketed respiratory products -- ipratropium, albuterol and bitolterol -- for use with the DPI, have had discussions with the FDA, and are now preparing IND submissions.